ストックスクリーナーアプリを入手
9.62
6.89%
0.62
プレマーケット:
9.60
-0.02
-0.21%
前日終値:
$9.00
開ける：
$9.03
24時間の取引高:
2.34M
Relative Volume:
2.47
時価総額：
$936.43M
収益：
$1.91M
当期純損益:
$-94.23M
株価収益率:
-3.7718
EPS:
-2.5505
ネットキャッシュフロー:
$-79.76M
1週間 パフォーマンス:
+32.87%
1か月 パフォーマンス:
+69.07%
6か月 パフォーマンス:
+173.30%
1年 パフォーマンス:
+197.83%
1日の値動き範囲:
$9.03
$9.79
1週間の範囲:
$7.22
$9.79
52週間の値動き範囲:
$2.85
$9.79
Anteris Technologies Global Corp Stock (AVR) Company Profile
名前
Anteris Technologies Global Corp
セクター
電話
651-493-0606
住所
860 BLUE GENTIAN ROAD, EAGAN
Compare AVR vs ISRG, BDX, ALC, MDLN, RMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVR
Anteris Technologies Global Corp
|
9.62 | 876.08M | 1.91M | -94.23M | -79.76M | -2.5505 |
ISRG
Intuitive Surgical Inc
|
438.10 | 155.76B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
147.63 | 40.30B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
67.78 | 33.13B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
37.01 | 31.37B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
208.05 | 30.31B | 5.54B | 1.52B | 1.74B | 10.37 |
Anteris Technologies Global Corp Stock (AVR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | Cantor Fitzgerald | Overweight |
| 2026-03-11 | 開始されました | Wells Fargo | Overweight |
| 2025-01-08 | 開始されました | Lake Street | Buy |
| 2025-01-07 | 開始されました | Barclays | Overweight |
| 2025-01-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-01-07 | 開始されました | TD Cowen | Buy |
すべてを表示
Anteris Technologies Global Corp (AVR) 最新ニュース
Anteris Technologies Global Corp plans to issue up to $250 million in common stock through TD Cowen as the underwriter. - Bitget
Anteris Technologies Global Launches $250 Million ATM Offering Under Sales Agreement With TD Cowen - TradingView
Anteris (NASDAQ: AVR) launches $250M at-the-market share program - Stock Titan
Anteris Technologies (NASDAQ: AVR) establishes $250M ATM with TD Cowen - Stock Titan
ChartWatch ASX Scans: Brazilian Rare Earths, Echoiq, Weebit Nano. Anteris Technologies, Global X Semiconductor ETF - Market Index
Anteris Technologies Global : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Director Susan Knight reports initial insider status at Anteris (NASDAQ: AVR) - Stock Titan
Number of shareholders of Anteris Technologies Global Corp. – NASDAQ:AVR - TradingView
Nantahala holds 6,143,154 shares of Anteris (AVR) as of 03/31/2026 - Stock Titan
AVR Maintained by Barclays -- Price Target Raised to $18.00 - GuruFocus
Anteris Technologies Global Corp. (AVR) Gets a Buy from TD Cowen - The Globe and Mail
Anteris Announces Results for the First Quarter of 2026 - Sahm
Anteris Technologies Adds Experienced Financial Leaders to Board - The Globe and Mail
TradingKey - TradingKey
Here's Why We're Not Too Worried About Anteris Technologies Global's (ASX:AVR) Cash Burn Situation - Yahoo Finance
How Should Investors Value Anteris Technologies Global Corp (AVR - GuruFocus
Anteris Technologies appoints two directors to board - Investing.com
Anteris Technologies appoints two directors to board By Investing.com - Investing.com South Africa
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors - The Manila Times
Two experienced directors join Anteris as it advances DurAVR heart valve - Stock Titan
Anteris Technologies Reports Q1 2026 Results: $320M Raised and Key Milestones in PARADIGM Trial for DurAVR THV System - Minichart
Anteris Technologies Global Corp. Files Form 8-K for Nasdaq Listing and Company Details (May 12, 2026) - Minichart
Anteris Technologies Global adds Susan Knight and Stephen Denaro to board - Investing.com
Anteris Technologies Global Starts US PARADIGM Trial Enrolment - smallcaps.com.au
Anteris Technologies Posts Narrower Q1 Loss, Lower Net Sales - Moomoo
Why Market Is Bullish on Anteris Technologies (ASX:AVR) Today - Kalkine
Anteris adds seasoned finance leaders to board as structural heart push continues - TipRanks
Anteris Technologies Q1 2026 Results: DurAVR™ THV Trial Progresses, Cash Balance at $64.9 Million - geneonline.com
Anteris Technologies Global Corp reports results for the quarter ended March 31Earnings Summary - TradingView
AVR: DurAVRⓇ THV system adoption grows, with Q1 2026 payments to related parties at US$2.3M - TradingView
Anteris Technologies Global Corp. 1Q 2026: Revenue $494K, EPS ($0.28) — 10-Q Summary - TradingView
Anteris Technologies (Nasdaq: AVR) posts Q1 2026 loss, raises $320M for DurAVR trial - Stock Titan
Anteris Technologies Global Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Anteris Technologies Global Corp at Barclays Global Healthcare Conference Transcript - GuruFocus
Anteris Technologies Global Corp expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Anteris secures US Medicare coverage for PARADIGM Trial as DurAVR study advances | ASX:AVR, NASDAQ:AVR - Proactive financial news
Anteris secures US Medicare coverage for PARADIGM Trial as DurAVR study advances - Yahoo Finance
Anteris Technologies Enrolls First US Patients in PARADIGM Trial; Shares Up 6% - marketscreener.com
First U.S. patients enrolled in Anteris heart valve trial By Investing.com - Investing.com South Africa
Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial - The Manila Times
Anteris Technologies begins U.S. enrollment in heart valve trial - StreetInsider
First U.S. patients enter Anteris heart valve trial for stenosis - Stock Titan
Analysts Offer Insights on Healthcare Companies: Anteris Technologies Global Corp. (AVR) and Siemens Healthineers AG (OtherSEMHF) - The Globe and Mail
Anteris Sees CDI Decline as Investors Shift to Nasdaq-Listed Common Stock - TipRanks
Sio Capital (AVR) reports 5.38M shares, 5.54% stake as of Mar 31, 2026 - Stock Titan
AVR Stock Price, Quote & Chart | ANTERIS TECHNOLOGIES GLOBAL (NASDAQ:AVR) - ChartMill
Anteris Ends v2vmedtech Development Agreement, Limits Exposure - The Globe and Mail
Anteris Technologies Global Corp. (NASDAQ: AVR) registers 9.10M shares; discontinues v2v contributions - Stock Titan
Anteris Technologies Exits v2vmedtech Development Agreement, to Pay $400,000 Break Fee, Shares Up 3% - marketscreener.com
Anteris Technologies Exits V2vmedtech Development Agreement, to Pay $400,000 Break Fee, Shares Up 3% - 富途牛牛
Anteris Walks Away From v2vmedtech Funding Deal With Limited Financial Impact - TipRanks
Anteris Technologies Global Corp (AVR) 財務データ
収益
当期純利益
現金流量
EPS
0.79%
0.48%
大文字化:
|
ボリューム (24 時間):